• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于探索非酒精性脂肪性肝病和脂肪性肝炎新疗法的天然产物。

Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis.

作者信息

Li Haiyan, Guan Ting, Qin Shi, Xu Qihao, Yin Lina, Hu Qingzhong

机构信息

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 232 East Waihuan Road, Panyu, Guangzhou, China.

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 232 East Waihuan Road, Panyu, Guangzhou, China.

出版信息

Drug Discov Today. 2023 Mar;28(3):103471. doi: 10.1016/j.drudis.2022.103471. Epub 2023 Jan 5.

DOI:10.1016/j.drudis.2022.103471
PMID:36610488
Abstract

Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are hepatic manifestations of systemic metabolic dysfunction, which affect one-quarter of the adult population worldwide as estimated, and exhibit high risk in progressing to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Current drug discovery focuses on modifying homeostasis of lipids, carbohydrates, and cholesterol, as well as inhibiting inflammation and fibrogenesis. Many natural products show promising activities on various molecular targets involving these mechanisms; however, they have not been fully exploited. Since some compounds are components of healthy food, they may be employed in chemoprevention as adjuvants to lifestyle modification, while natural products such as alkaloids and sesquiterpenoids could serve as promising starting points for structural modifications and deserve further development.

摘要

非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)是全身代谢功能障碍的肝脏表现,据估计,全球四分之一的成年人受其影响,并且进展为肝纤维化、肝硬化和肝细胞癌的风险很高。当前的药物研发集中在调节脂质、碳水化合物和胆固醇的稳态,以及抑制炎症和纤维化形成。许多天然产物在涉及这些机制的各种分子靶点上显示出有前景的活性;然而,它们尚未得到充分利用。由于一些化合物是健康食品的成分,它们可作为生活方式改变的辅助手段用于化学预防,而生物碱和倍半萜类等天然产物可作为有前景的结构修饰起点,值得进一步开发。

相似文献

1
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis.用于探索非酒精性脂肪性肝病和脂肪性肝炎新疗法的天然产物。
Drug Discov Today. 2023 Mar;28(3):103471. doi: 10.1016/j.drudis.2022.103471. Epub 2023 Jan 5.
2
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
3
Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).代谢相关脂肪性肝病(MAFLD)中致纤维化途径。
Int J Mol Sci. 2022 Jun 23;23(13):6996. doi: 10.3390/ijms23136996.
4
The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.美国生活方式引起的肥胖综合征饮食在雄性和雌性啮齿动物中再现了非酒精性脂肪性肝病和非酒精性脂肪性肝炎的临床和转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2020 Sep 1;319(3):G345-G360. doi: 10.1152/ajpgi.00055.2020. Epub 2020 Aug 5.
5
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的免疫相关发病机制和治疗策略。
Arch Pharm Res. 2022 Apr;45(4):229-244. doi: 10.1007/s12272-022-01379-1. Epub 2022 Apr 7.
6
Immune-metabolic interactions in homeostasis and the progression to NASH.免疫代谢相互作用在稳态和进展为 NASH 中的作用。
Trends Endocrinol Metab. 2022 Oct;33(10):690-709. doi: 10.1016/j.tem.2022.07.001. Epub 2022 Aug 10.
7
Recent updates on targeting the molecular mediators of NAFLD.NAFLD 分子介质靶向治疗的最新进展。
J Mol Med (Berl). 2023 Feb;101(1-2):101-124. doi: 10.1007/s00109-022-02282-4. Epub 2023 Feb 16.
8
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前药物治疗方法。
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
9
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制:非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.
10
Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.新兴的非酒精性脂肪性肝病治疗靶点:来自近期基础研究的证据。
World J Gastroenterol. 2023 Jan 7;29(1):75-95. doi: 10.3748/wjg.v29.i1.75.

引用本文的文献

1
Exosomal circRNA: emerging insights into cancer progression and clinical application potential.外泌体环状 RNA:癌症进展及临床应用潜力的新见解。
J Hematol Oncol. 2023 Jun 26;16(1):67. doi: 10.1186/s13045-023-01452-2.